Our proprietary methodology:

actionable, risk prediction in stages 1-3b.

Our 3-part, proprietary methodology – bioprognosisTM for kidney health – provides risk assessment for rapid progressive decline in kidney function in stages 1-3b, when it has the best chance for improving outcomes and promoting overall patient health.

KidneyIntelX Has Received Breakthrough Device Designation from the FDA for Chronic Kidney Disease Prognosis

1

Proprietary biomarkers

Biological factors that are clinically demonstrated – in multiple studies – to be most prognostic for kidney disease (TNFR1, TNFR2, KIM-1).

2

Select clinical features

7 select data points from a veteran patient’s health record (eGFR, UACR, serum calcium, HbA1c, systolic BP, platelets, AST) that are indicative of kidney/other key organ health or dysfunction.

3

Validated algorithm

Machine learning combines these diverse and proprietary data inputs to maximize their value through a veteran-specific risk score

4

Yields a clear and actionable test report:

Risk score + guideline-recommended clinical pathway to help clinicians make medical decisions today and tomorrow

Low Risk Result

(5 to 45)

Approximately 50% of patients tested with KidneyIntelX are expected to receive a low-risk score. A low-risk score (“green”) means that your adult patient with type 2 diabetes and chronic kidney disease stages 1-3b, is at the lowest risk for progressive decline in kidney function. Clinical studies have shown that the risk that an individual with this score will experience such a decline over the next five years is < 10%.

Intermediate Risk Result

(50 to 85)

Approximately 35% of all patients tested with KidneyIntelX are expected to receive an intermediate risk score. With an intermediate-risk score (“orange”), you may recommend that the patient monitors his/her kidney health more frequently, which may include additional visits, additional blood work, some lifestyle changes and potentially, the introduction of specialized medication.

High Risk Result

(90 to 100)

Approximately 15% of patients tested with KidneyIntelX are expected to receive a high-risk score, which means that they have a 60% or higher chance of experiencing progressive decline in kidney function over the next five years. With a high-risk score, you may act more quickly and aggressively in the treatment of your patients’ kidney disease, which could include more frequent follow-up visits, referrals to a nephrologist, maximizing current medications and/or introducing new medications.

Request a Meeting
GSA order form
About Test
See Evidence
Why Early Stage Risk Assessment?